Tweets
ACR Comments on JAK Inhibitors and FDA Announcement
https://t.co/zDYInRQjTl https://t.co/xu9A8I7Frs
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
Baricitinib & Tofacitinib are effective in COVID-19 pts. These drugs are expensive; baricitinib is $44/tablet, but much lower for generics worldwide. 14 day course of TOFA would be >$1,400 in the US (but $600 in France, $25 in India) https://t.co/r2cn1H2z8i
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
NICE (UK) has recommended tofacitinib as an option for treating active polyarticular juvenile arthritis and juvenile psoriatic arthritis in people 2 years and older. https://t.co/9iLqzo36aD
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
Surveys of 125 clinic patients suggests an improved pt experience by Standardizing appt phone call script, updating appointment package, include a clinic visit prep checklist, to improve pt preparedness and reduce clinic cycle time. https://t.co/5sfBFpag8V
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
ICYMI:
Causes of DYSGEUSIA (metallic taste):
- Antibiotics (clarithromycin, metronidazole tetracycline), Allopurinol, captopril,
Lithium, Methazolamide, Metformin, Lunesta and more... heres a video discussion on this. https://t.co/FphprLh1Sf https://t.co/1wkjQxA9UZ https://t.co/kAFaKGiHiG
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
Cytokine Storm Overview Available for Download!
https://t.co/XRlx3OJDeR https://t.co/9mGnopNBTs
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
MMWR reports that during the COVID Delta variant era, Vaccination against COVID-19:
- Reduces risk of COVID-19 infection 5X
- Reduces risk of COVID-19 Hospitalization >10X
- Reduces risk of COVID-19 DEATH 10X
https://t.co/rMRY84xX5F
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
Probenecid, an OAT3 inhibitor, has inhibitory effects on RNA viruses (influenza, RSV) & decreases ACE2 expression. May have utility in COVID-19 as it was shown to inhibit SARS-CoV-2 replication in animal models https://t.co/MClSjpqpSa
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
ICYMI:
https://t.co/wM1iRxtHvk
The interleukin-6 inhibitor, tocilizumab (TCZ), was studied in a cohort of difficult systemic sclerosis (SSc) and was shown to be effective in refractory joint and skin disease with good long-term retention rates and disease stabilization. https://t.co/A8dfCksp3b
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
A retrospective study of systemic sclerosis patients shows that acute hospitalization and mortality were not uncommon and were often linked to SSc-related lung disease.
#RheumNow
https://t.co/s5wSlndTrt https://t.co/KHz9LYZVAK
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
J Hopkins study of 524 myositis-specific Ab positive pts shows that while 91% met 2017 EULAR/ACR criteria for Dx of myositis, 20% of HMGCR+ & 50% anti-PL7 did not classify as myositis; ~10% anti-SRP & HMGCR were dx as inclusion body myositis https://t.co/jcIn6SzbGG
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
NOVEL: CRISPR-Cas9 genome editing of stem cells allows sensing of local inflammation & proportionally secrete a programmed anti-inflammatory biologic drug. Stem cells implanted in cartilage can prevent pain and inflammatory damage https://t.co/VNIgnvDU2C
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
